Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

By M. Soda, Y. L. Choi, Munehiro Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, K. Kurashina, Hisashi Hatanaka and 8 more. Nature, 2007

5,249 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/aa270cc2d7e39b7b19dbabcb57cf87aa54078577

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Manel Esteller
2. Peter W. Laird
3. Heng Li
4. S. Baylin
5. Steven L. Salzberg
6. Eric S. Lander
7. Richard Durbin
8. Jill P. Mesirov

In Oncology

1. William Pao
2. Peter J. Campbell
3. Padmanee Sharma
4. Gregory Riely
5. Vincent A. Miller
6. M. Kris
7. James P. Allison
8. Nicolas Stransky

In Pulmonary and Respiratory Medicine

1. William Pao
2. Gregory Riely
3. Vincent A. Miller
4. B. Hughes
5. B. Chan
6. J. Chmielecki
7. M. Kris
8. Marc Ladanyi

Citations in the corpus

• Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing (2008, background): “, a prediction substantiated by recent discoveries of an EML4-ALK fusion in non-small-cell lung cance”
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010, background): “Another 5% of tumours harbour translocations in anaplastic lymphoma kinase ( ALK”
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors (2013, neutral): “The most common of these rearrangements involves a pericentric inversion on the short arm of chromosome 2, inv(2)(p21p23), which creates a fusion gene encoding the amino-terminal portion of EML4 (2p21) and the intracellular region of ALK (2p23), genes that are normally approximately 13 Mb apart.(8,2”
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer (2012, positive): “In 2007, an ALK gene rearrangement (ALK+) in which the 5’ end of the echinoderm microtubule-associated protein-like 4 (EML4) gene was fused to the 3’ portion of ALK was identified in NSCLC (5).”